Lipoprotein lipase during heparin infusion: Lower activity in hemodialysis patients

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 63, Issue 1, 2003, Pages 45-54

  Nasstrom B ^a   Olivecrona, G ^a   Olivecrona, T ^a   Stegmayr, Bernd G ^a,b  

^a UMEÅ UNIVERSITY   (Sweden)

^b Medicinkliniken   (Sweden)

Author keywords

Cholesterol; Dialysis; Lipase turnover; Post heparin plasma; Triglycerides; Uremia

Indexed keywords

HEPARIN; LIPOPROTEIN LIPASE; TRIACYLGLYCEROL;

ADULT; AGE; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; GENDER; HEMODIALYSIS; HUMAN; LIPOPROTEIN METABOLISM; MALE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0346774831     PISSN: 00365513     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365510308582     Document Type: Article

References (32)

1. Yukawa S, Mune M, Yamada Y, Otani H, Kishino M, Tone Y. Ongoing clinical trials of lipid reduction therapy in patients with renal disease Kidney Int Suppl 1999; 71: S141-3.
2. Raine AE, Margreiter R, Brunner FP, Ehrich JH, Geerlings W, Landais P, Loirat C, Mallick NP, Selwood NH, Tufveson G, Valderrabano F. Report on management of renal failure in Europe, XXII, 1991 Nephrol Dial Transplant 1992; 7: 7-35.
3. LaRosa JC, Hunninghake D, Bush D, Criqui MH, Getz GS, Gotto AM, Jr., Grundy SM, Rakita L, Robertson RM, Weisfeldt ML, Cleeman JI. The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The Task Force on Cholesterol Issues, American Heart Association Circulation 1990; 81: 1721-33.
4. Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men Am J Cardiol 1996; 77: 1179-84.
5. Koch M, Kutkuhn B, Trenkwalder E, Bach D, Grabensee B, Dieplinger H, Kronenberg F. Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein(a) phenotypes predict coronary artery disease in hemodialysis patients J Am Soc Nephrol 1997; 8: 1889-98.
6. Bagdade JD, Porte D, Jr, Bierman EL. Hypertriglyceridemia. A metabolic consequence of chronic renal failure N Engl J Med 1968; 279: 181-5.
7. Arnadottir M, Nilsson-Ehle P. Parathyroid hormone is not an inhibitor of lipoprotein lipase activity Nephrol Dial Transplant 1994; 9: 1586-9.
8. Shoji T, Nishizawa Y, Kawagishi T, Tanaka M, Kawasaki K, Tabata T, Inoue T, Morii H. Atherogenic lipoprotein changes in the absence of hyperlipidemia in patients with chronic renal failure treated by hemodialysis Atherosclerosis 1997; 131: 229-36.
9. Samuelsson O, Attman PO, Knight-Gibson C, Kron B, Larsson R, Mulec H, Weiss L, Alaupovic P. Lipoprotein abnormalities without hyperlipidaemia in moderate renal insufficiency Nephrol Dial Transplant 1994; 9: 1580-5.
10. Goldberg IJ. Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis J Lipid Res 1996; 37: 693-707.
11. Olivecrona T, Olivecrona G. Lipoprotein and hepatic lipases in lipoprotein metabolism In: Betteridge DJ, Illingworth DR, Shepard J, editors. Lipoproteins in health and disease. London: Arnold, 1999. p. 223-46.
12. Mead JR, Cryer A, Ramji DP. Lipoprotein lipase, a key role in atherosclerosis? FEBS Lett 1999; 462: 1-6.
13. Olivecrona T, Olivecrona G. Determination and clinical significance of lipoprotein lipase and hepatic lipase In: Rifai N, Warnick G, Dominiczak M, editors. Handbook of lipoprotein testing. Washington DC: AACC Press, 2000. p. 479-97.
14. Bagdade JD. Uremic lipemia. An unrecognized abnormality in triglyceride production and removal Arch Intern Med 1991; 126: 875-81.
15. Chan MK, Persaud J, Varghese Z, Moorhead JF. Pathogenic roles of post-heparin lipases in lipid abnormalities in hemodialysis patients Kidney Int 1984; 25: 812-8.
16. Goldberg A, Sherrard DJ, Brunzell JD. Adipose tissue lipoprotein lipase in chronic hemodialysis: role in plasma triglyceride metabolism J Clin Endocrinol Metab 1978; 47: 1173-82.
17. Roullet JB, Lacour B, Yvert JP, Prat JJ, Drueke T. Factors of increase in serum triglyceride-rich lipoproteins in uremic rats Kidney Int 1985; 27: 420-5.
18. Vaziri ND, Liang K. Down-regulation of tissue lipoprotein lipase expression in experimental chronic renal failure Kidney Int 1996; 50: 1928-35.
19. Murase T, Cattran DC, Rubenstein B, Steiner G. Inhibition of lipoprotein lipase by uremic plasma, a possible cause of hypertriglyceridemia Metabolism 1975; 24: 1279-86.
20. Cheung AK, Parker CJ, Ren K, Iverius PH. Increased lipase inhibition in uremia: identification of pre-beta-HDL as a major inhibitor in normal and uremic plasma Kidney Int 1996; 49: 1360-71.
21. Arnadottir M, Dallongeville J, Fruchart JC, Nilsson-Ehle P. Very-low-density lipoprotein of uremic patients is a poor substrate for bovine lipoprotein lipase in vitro Metabolism 1996; 45: 686-90.
22. Chevreuil O, Hultin M, Ostergaard P, Olivecrona T. Depletion of lipoprotein lipase after heparin administration Arterioscler Thromb 1993; 13: 1391-6.
23. Nestel PJ. The depletion and restoration of post-heparin lipolytic activity in the human forearm Proc Soc Exp Biol Med 1970; 134: 896-9.
24. Schrader J Andersson LO, Armstrong VW, Kundt M, Stibbe W, Scheler F. Lipolytic effects of heparin and low molecular weight heparin and their importance in hemodialysis Semin Thromb Hemos 1990; 16 Suppl: 41-5.
25. Weintraub M, Rassin T, Eisenberg S, Ringel Y, Grosskopf I, Iaina A, Charach G, Liron M, Rubinstein A. Continuous intravenous heparin administration in humans causes a decrease in serum lipolytic activity and accumulation of chylomicrons in circulation J Lipid Res 1994; 35: 229-38.
26. Nasstrom B, Olivecrona G, Olivecrona T, Stegmayr BG. Lipoprotein lipase during continuous heparin infusion: tissue stores become partially depleted J Lab Clin Med 2001; 138: 206-13.
27. Majerus P, Broze GJ, Miletich J, Tollefsen D. Anticoagulant, thrombolytic, and antiplatelet drugs In: Hardman J, Limbird L, Molinoff P, Ruddon R, Goodman Gilman A, editors. Goodman & Gilman's the pharmacological basis of therapeutics: 9th ed. London: McGraw-Hill, 1996. p. 14;1341-59.
28. Koerber JM, Smythe MA, Begle RL, Mattson JC, Kershaw BP, Westley SJ. Correlation of activated clotting time and activated partial thromboplastin time to plasma heparin concentration Pharmacotherapy 1999; 19: 922-31.
29. Vilaro S, Llobera M, Bengtsson-Olivecrona G, Olivecrona T. Lipoprotein lipase uptake by the liver: localization, turnover, and metabolic role Am J Physiol 1988; 254: G711-22.
30. Thompson PD, Kantor MA, Cullinane EM, Sady SP, Saritelli A, Herbert PN. Postheparin plasma lipolytic activities in physically active and sedentary men after varying and repeated doses of intravenous heparin Metabolism 1986; 35: 999-1004.
31. Hahn P. Abolishment of alimentary lipemia following injection of heparin Science 1943; 98: 19-20.
32. Alsayed N, Rebourcet R. Abnormal concentrations of CII, CIII, and E apolipoproteins among apolipoprotein B-containing, B-free, and A-I-containing lipoprotein particles in hemodialysis patients Clin Chem 1991; 37: 387-93.